NO973107L - Programmerte celledödgener og proteiner - Google Patents
Programmerte celledödgener og proteinerInfo
- Publication number
- NO973107L NO973107L NO973107A NO973107A NO973107L NO 973107 L NO973107 L NO 973107L NO 973107 A NO973107 A NO 973107A NO 973107 A NO973107 A NO 973107A NO 973107 L NO973107 L NO 973107L
- Authority
- NO
- Norway
- Prior art keywords
- ich
- ced
- cells
- cell death
- gene
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims description 259
- 102000004169 proteins and genes Human genes 0.000 title claims description 111
- 238000003782 apoptosis assay Methods 0.000 title claims description 78
- 230000005522 programmed cell death Effects 0.000 title claims description 78
- 239000002299 complementary DNA Substances 0.000 claims description 101
- 108020004414 DNA Proteins 0.000 claims description 67
- 238000000034 method Methods 0.000 claims description 61
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 claims description 51
- 239000013598 vector Substances 0.000 claims description 41
- 230000000694 effects Effects 0.000 claims description 37
- 230000001105 regulatory effect Effects 0.000 claims description 34
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 29
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims description 26
- 239000013604 expression vector Substances 0.000 claims description 26
- 210000001541 thymus gland Anatomy 0.000 claims description 21
- 102000004190 Enzymes Human genes 0.000 claims description 17
- 108090000790 Enzymes Proteins 0.000 claims description 17
- 230000034994 death Effects 0.000 claims description 14
- 230000002255 enzymatic effect Effects 0.000 claims description 9
- 102000000589 Interleukin-1 Human genes 0.000 claims description 8
- 108010002352 Interleukin-1 Proteins 0.000 claims description 8
- 230000001965 increasing effect Effects 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 7
- 230000002401 inhibitory effect Effects 0.000 claims description 7
- 230000003169 placental effect Effects 0.000 claims description 6
- 102000053602 DNA Human genes 0.000 claims description 4
- 230000001737 promoting effect Effects 0.000 claims description 4
- 101150067246 crmA gene Proteins 0.000 claims description 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 102000003390 tumor necrosis factor Human genes 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 397
- 101150055276 ced-3 gene Proteins 0.000 description 298
- 230000030833 cell death Effects 0.000 description 140
- 230000014509 gene expression Effects 0.000 description 124
- 235000018102 proteins Nutrition 0.000 description 97
- 101100007739 Neosartorya fumigata (strain ATCC MYA-4609 / Af293 / CBS 101355 / FGSC A1100) crmA gene Proteins 0.000 description 78
- 150000001413 amino acids Chemical group 0.000 description 73
- 101100059157 Mus musculus Casp2 gene Proteins 0.000 description 65
- 102100040247 Tumor necrosis factor Human genes 0.000 description 62
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 50
- 241000699666 Mus <mouse, genus> Species 0.000 description 45
- 108020004999 messenger RNA Proteins 0.000 description 44
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 42
- 230000035772 mutation Effects 0.000 description 40
- 235000001014 amino acid Nutrition 0.000 description 37
- 229940024606 amino acid Drugs 0.000 description 37
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 36
- 239000012634 fragment Substances 0.000 description 36
- 239000000523 sample Substances 0.000 description 36
- 230000002018 overexpression Effects 0.000 description 34
- 101150112018 ced-4 gene Proteins 0.000 description 27
- 230000006870 function Effects 0.000 description 27
- 108091028043 Nucleic acid sequence Proteins 0.000 description 26
- 238000002474 experimental method Methods 0.000 description 26
- 238000003752 polymerase chain reaction Methods 0.000 description 26
- 239000000047 product Substances 0.000 description 26
- 241001465754 Metazoa Species 0.000 description 24
- 108700026244 Open Reading Frames Proteins 0.000 description 23
- 239000013612 plasmid Substances 0.000 description 23
- 108091026890 Coding region Proteins 0.000 description 22
- 241001529936 Murinae Species 0.000 description 22
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 21
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 21
- 230000006907 apoptotic process Effects 0.000 description 21
- 235000004400 serine Nutrition 0.000 description 21
- 210000004556 brain Anatomy 0.000 description 20
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 19
- 230000002068 genetic effect Effects 0.000 description 19
- 238000010367 cloning Methods 0.000 description 18
- 238000003776 cleavage reaction Methods 0.000 description 17
- 238000000636 Northern blotting Methods 0.000 description 16
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 16
- 230000007017 scission Effects 0.000 description 16
- 230000014616 translation Effects 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 14
- 238000011161 development Methods 0.000 description 14
- 230000018109 developmental process Effects 0.000 description 14
- 101150066555 lacZ gene Proteins 0.000 description 14
- 241000894007 species Species 0.000 description 14
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 13
- 241000287828 Gallus gallus Species 0.000 description 13
- 241000244206 Nematoda Species 0.000 description 13
- 239000003112 inhibitor Substances 0.000 description 13
- 210000002569 neuron Anatomy 0.000 description 13
- 108090000765 processed proteins & peptides Proteins 0.000 description 13
- 238000013519 translation Methods 0.000 description 13
- 230000004913 activation Effects 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 230000004927 fusion Effects 0.000 description 12
- 150000007523 nucleic acids Chemical class 0.000 description 12
- 239000002773 nucleotide Substances 0.000 description 11
- 125000003729 nucleotide group Chemical group 0.000 description 11
- 238000013518 transcription Methods 0.000 description 11
- 230000035897 transcription Effects 0.000 description 11
- 238000001890 transfection Methods 0.000 description 11
- 108700028369 Alleles Proteins 0.000 description 10
- 108020005544 Antisense RNA Proteins 0.000 description 10
- 108020004705 Codon Proteins 0.000 description 10
- 230000033228 biological regulation Effects 0.000 description 10
- 101150046002 ced-1 gene Proteins 0.000 description 10
- 239000003184 complementary RNA Substances 0.000 description 10
- 229960004452 methionine Drugs 0.000 description 10
- 102000039446 nucleic acids Human genes 0.000 description 10
- 108020004707 nucleic acids Proteins 0.000 description 10
- 230000000638 stimulation Effects 0.000 description 10
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 9
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 9
- 101100044796 Caenorhabditis elegans unc-26 gene Proteins 0.000 description 9
- 101100048438 Caenorhabditis elegans unc-30 gene Proteins 0.000 description 9
- 241000588724 Escherichia coli Species 0.000 description 9
- 102100036089 Fascin Human genes 0.000 description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 9
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 239000002158 endotoxin Substances 0.000 description 9
- 238000009396 hybridization Methods 0.000 description 9
- 229930182817 methionine Natural products 0.000 description 9
- 230000037361 pathway Effects 0.000 description 9
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- 101150085100 unc-31 gene Proteins 0.000 description 9
- 241000244201 Caenorhabditis briggsae Species 0.000 description 8
- 101100011368 Caenorhabditis elegans egl-1 gene Proteins 0.000 description 8
- 244000183685 Citrus aurantium Species 0.000 description 8
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 8
- 108091092195 Intron Proteins 0.000 description 8
- 101150039936 ced-9 gene Proteins 0.000 description 8
- 230000001413 cellular effect Effects 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 210000000349 chromosome Anatomy 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 229920006008 lipopolysaccharide Polymers 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 238000010369 molecular cloning Methods 0.000 description 8
- 210000002826 placenta Anatomy 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 7
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 7
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 7
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 7
- 230000000692 anti-sense effect Effects 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 210000004899 c-terminal region Anatomy 0.000 description 7
- 235000018417 cysteine Nutrition 0.000 description 7
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 7
- 230000003013 cytotoxicity Effects 0.000 description 7
- 231100000135 cytotoxicity Toxicity 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 230000006698 induction Effects 0.000 description 7
- 108010027775 interleukin-1beta-converting enzyme inhibitor Proteins 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- 230000002103 transcriptional effect Effects 0.000 description 7
- 102000007469 Actins Human genes 0.000 description 6
- 108010085238 Actins Proteins 0.000 description 6
- 108020004491 Antisense DNA Proteins 0.000 description 6
- 108091036066 Three prime untranslated region Proteins 0.000 description 6
- 239000003816 antisense DNA Substances 0.000 description 6
- 239000013599 cloning vector Substances 0.000 description 6
- 230000001472 cytotoxic effect Effects 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000012894 fetal calf serum Substances 0.000 description 6
- 230000001605 fetal effect Effects 0.000 description 6
- 210000002950 fibroblast Anatomy 0.000 description 6
- 210000002216 heart Anatomy 0.000 description 6
- 230000010196 hermaphroditism Effects 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 108020003519 protein disulfide isomerase Proteins 0.000 description 6
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 230000035899 viability Effects 0.000 description 6
- 108010005843 Cysteine Proteases Proteins 0.000 description 5
- 102000005927 Cysteine Proteases Human genes 0.000 description 5
- 239000003298 DNA probe Substances 0.000 description 5
- 108700020796 Oncogene Proteins 0.000 description 5
- 102000035195 Peptidases Human genes 0.000 description 5
- 108091005804 Peptidases Proteins 0.000 description 5
- 239000004365 Protease Substances 0.000 description 5
- 108020005067 RNA Splice Sites Proteins 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 108010005774 beta-Galactosidase Proteins 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 239000013592 cell lysate Substances 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 231100000433 cytotoxic Toxicity 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000013020 embryo development Effects 0.000 description 5
- 230000028709 inflammatory response Effects 0.000 description 5
- 230000000977 initiatory effect Effects 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 238000000520 microinjection Methods 0.000 description 5
- 230000001537 neural effect Effects 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 230000002797 proteolythic effect Effects 0.000 description 5
- 230000001177 retroviral effect Effects 0.000 description 5
- 150000003355 serines Chemical class 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 230000009466 transformation Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 108020004635 Complementary DNA Proteins 0.000 description 4
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 108010025020 Nerve Growth Factor Proteins 0.000 description 4
- 102000015336 Nerve Growth Factor Human genes 0.000 description 4
- 101150100341 PEX2 gene Proteins 0.000 description 4
- 101150118397 Pex5l gene Proteins 0.000 description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 description 4
- 102000012479 Serine Proteases Human genes 0.000 description 4
- 108010022999 Serine Proteases Proteins 0.000 description 4
- 108050000761 Serpin Proteins 0.000 description 4
- 102000008847 Serpin Human genes 0.000 description 4
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 102000005936 beta-Galactosidase Human genes 0.000 description 4
- 230000004641 brain development Effects 0.000 description 4
- 231100000504 carcinogenesis Toxicity 0.000 description 4
- 230000032677 cell aging Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 210000003527 eukaryotic cell Anatomy 0.000 description 4
- 230000037433 frameshift Effects 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000003387 muscular Effects 0.000 description 4
- 208000010125 myocardial infarction Diseases 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 230000010309 neoplastic transformation Effects 0.000 description 4
- 208000015122 neurodegenerative disease Diseases 0.000 description 4
- 230000016273 neuron death Effects 0.000 description 4
- 238000007899 nucleic acid hybridization Methods 0.000 description 4
- 230000017448 oviposition Effects 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 239000013600 plasmid vector Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 239000012679 serum free medium Substances 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 241000244203 Caenorhabditis elegans Species 0.000 description 3
- 101100502609 Caenorhabditis elegans fem-1 gene Proteins 0.000 description 3
- 101100074828 Caenorhabditis elegans lin-12 gene Proteins 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 108090000426 Caspase-1 Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 101100334582 Drosophila melanogaster Fem-1 gene Proteins 0.000 description 3
- 102000010911 Enzyme Precursors Human genes 0.000 description 3
- 108010062466 Enzyme Precursors Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108700024394 Exon Proteins 0.000 description 3
- 101150064015 FAS gene Proteins 0.000 description 3
- 102100036263 Glutamyl-tRNA(Gln) amidotransferase subunit C, mitochondrial Human genes 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 101001001786 Homo sapiens Glutamyl-tRNA(Gln) amidotransferase subunit C, mitochondrial Proteins 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 108091081024 Start codon Proteins 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 239000006180 TBST buffer Substances 0.000 description 3
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 229940009098 aspartate Drugs 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 230000002860 competitive effect Effects 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 239000003636 conditioned culture medium Substances 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 210000004748 cultured cell Anatomy 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 210000002257 embryonic structure Anatomy 0.000 description 3
- 102000018823 fas Receptor Human genes 0.000 description 3
- 108010052621 fas Receptor Proteins 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 210000003754 fetus Anatomy 0.000 description 3
- 230000003325 follicular Effects 0.000 description 3
- 231100000221 frame shift mutation induction Toxicity 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 210000003630 histaminocyte Anatomy 0.000 description 3
- 238000002744 homologous recombination Methods 0.000 description 3
- 230000006801 homologous recombination Effects 0.000 description 3
- 230000006882 induction of apoptosis Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 210000001161 mammalian embryo Anatomy 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 229940053128 nerve growth factor Drugs 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000004481 post-translational protein modification Effects 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 229950010131 puromycin Drugs 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000003001 serine protease inhibitor Substances 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 230000010474 transient expression Effects 0.000 description 3
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 101150090724 3 gene Proteins 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 208000003950 B-cell lymphoma Diseases 0.000 description 2
- 241000701822 Bovine papillomavirus Species 0.000 description 2
- 241000244202 Caenorhabditis Species 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- 108020003215 DNA Probes Proteins 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 102100031780 Endonuclease Human genes 0.000 description 2
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
- 102000001398 Granzyme Human genes 0.000 description 2
- 108060005986 Granzyme Proteins 0.000 description 2
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108020004485 Nonsense Codon Proteins 0.000 description 2
- 108091005461 Nucleic proteins Proteins 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 238000010222 PCR analysis Methods 0.000 description 2
- 244000203593 Piper nigrum Species 0.000 description 2
- 230000006819 RNA synthesis Effects 0.000 description 2
- 238000010240 RT-PCR analysis Methods 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000006721 cell death pathway Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000013611 chromosomal DNA Substances 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 201000003444 follicular lymphoma Diseases 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 101150064902 hlh-1 gene Proteins 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 101150072601 lin-14 gene Proteins 0.000 description 2
- -1 mICE Proteins 0.000 description 2
- 238000010841 mRNA extraction Methods 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000007479 molecular analysis Methods 0.000 description 2
- 108091027963 non-coding RNA Proteins 0.000 description 2
- 102000042567 non-coding RNA Human genes 0.000 description 2
- 230000037434 nonsense mutation Effects 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 210000001995 reticulocyte Anatomy 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000036303 septic shock Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000010473 stable expression Effects 0.000 description 2
- 238000012916 structural analysis Methods 0.000 description 2
- 230000002889 sympathetic effect Effects 0.000 description 2
- 230000005030 transcription termination Effects 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 230000001228 trophic effect Effects 0.000 description 2
- 238000003211 trypan blue cell staining Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- WKVZMKDXJFCMMD-UVWUDEKDSA-L (5ar,8ar,9r)-5-[[(2r,4ar,6r,7r,8r,8as)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one;azanide;n,3-bis(2-chloroethyl)-2-ox Chemical compound [NH2-].[NH2-].Cl[Pt+2]Cl.ClCCNP1(=O)OCCCN1CCCl.COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3C(O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 WKVZMKDXJFCMMD-UVWUDEKDSA-L 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- FVFVNNKYKYZTJU-UHFFFAOYSA-N 6-chloro-1,3,5-triazine-2,4-diamine Chemical group NC1=NC(N)=NC(Cl)=N1 FVFVNNKYKYZTJU-UHFFFAOYSA-N 0.000 description 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 1
- 108010087905 Adenovirus E1B Proteins Proteins 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 241000024188 Andala Species 0.000 description 1
- 241001156002 Anthonomus pomorum Species 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- DWBZEJHQQIURML-IMJSIDKUSA-N Asp-Ser Chemical group OC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(O)=O DWBZEJHQQIURML-IMJSIDKUSA-N 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 102000051485 Bcl-2 family Human genes 0.000 description 1
- 108700038897 Bcl-2 family Proteins 0.000 description 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
- 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 1
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 description 1
- 101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 description 1
- 101100178170 Caenorhabditis elegans unc-39 gene Proteins 0.000 description 1
- 101100347613 Caenorhabditis elegans unc-54 gene Proteins 0.000 description 1
- 101100539485 Caenorhabditis elegans unc-86 gene Proteins 0.000 description 1
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 1
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000700626 Cowpox virus Species 0.000 description 1
- 101000828805 Cowpox virus (strain Brighton Red) Serine proteinase inhibitor 2 Proteins 0.000 description 1
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 1
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 208000037487 Endotoxemia Diseases 0.000 description 1
- 101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108091092566 Extrachromosomal DNA Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 108010001515 Galectin 4 Proteins 0.000 description 1
- 101000834253 Gallus gallus Actin, cytoplasmic 1 Proteins 0.000 description 1
- 101000962067 Gallus gallus Neuroblastoma suppressor of tumorigenicity 1 Proteins 0.000 description 1
- 208000034951 Genetic Translocation Diseases 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 238000010867 Hoechst staining Methods 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000715398 Homo sapiens Caspase-1 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108700005090 Lethal Genes Proteins 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102100037611 Lysophospholipase Human genes 0.000 description 1
- 241000714177 Murine leukemia virus Species 0.000 description 1
- 101000715411 Mus musculus Caspase-1 Proteins 0.000 description 1
- 101000969137 Mus musculus Metallothionein-1 Proteins 0.000 description 1
- 101100357267 Mus musculus Rpl10a gene Proteins 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 240000002390 Pandanus odoratissimus Species 0.000 description 1
- 235000005311 Pandanus odoratissimus Nutrition 0.000 description 1
- 108010058864 Phospholipases A2 Proteins 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 101100268183 Rattus norvegicus Znf260 gene Proteins 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 239000012722 SDS sample buffer Substances 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- FFOKMZOAVHEWET-IMJSIDKUSA-N Ser-Cys Chemical group OC[C@H](N)C(=O)N[C@@H](CS)C(O)=O FFOKMZOAVHEWET-IMJSIDKUSA-N 0.000 description 1
- 102000011971 Sphingomyelin Phosphodiesterase Human genes 0.000 description 1
- 108010061312 Sphingomyelin Phosphodiesterase Proteins 0.000 description 1
- 101001095983 Staphylococcus aureus Protein rep Proteins 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108700026226 TATA Box Proteins 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- VPZKQTYZIVOJDV-LMVFSUKVSA-N Thr-Ala Chemical group C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(O)=O VPZKQTYZIVOJDV-LMVFSUKVSA-N 0.000 description 1
- 108010001244 Tli polymerase Proteins 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 1
- 108091005956 Type II transmembrane proteins Proteins 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- QPMSXSBEVQLBIL-CZRHPSIPSA-N ac1mix0p Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1.O([C@H]1[C@]2(OC)C=CC34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O QPMSXSBEVQLBIL-CZRHPSIPSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000002299 affinity electrophoresis Methods 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical group N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 108010028263 bacteriophage T3 RNA polymerase Proteins 0.000 description 1
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
- 108700000711 bcl-X Proteins 0.000 description 1
- 102000055104 bcl-X Human genes 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000003683 cardiac damage Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 101150046414 ce gene Proteins 0.000 description 1
- 230000000453 cell autonomous effect Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000002032 cellular defenses Effects 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- SMNPLAKEGAEPJD-UHFFFAOYSA-N chembl34922 Chemical compound Cl.Cl.Cl.C1CN(C)CCN1C1=CC=C(NC(=N2)C=3C=C4N=C(NC4=CC=3)C=3C=CC(O)=CC=3)C2=C1 SMNPLAKEGAEPJD-UHFFFAOYSA-N 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 201000003740 cowpox Diseases 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 108010052305 exodeoxyribonuclease III Proteins 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 210000002458 fetal heart Anatomy 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000000574 ganglionic effect Effects 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 102000054767 gene variant Human genes 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 150000002333 glycines Chemical class 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000010661 induction of programmed cell death Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000003125 jurkat cell Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 230000001418 larval effect Effects 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000004777 loss-of-function mutation Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000018901 negative regulation of programmed cell death Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000007514 neuronal growth Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 229950000964 pepstatin Drugs 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 108010073128 phosphatidylcholine-specific phospholipase C Proteins 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000018855 positive regulation of programmed cell death Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 210000002243 primary neuron Anatomy 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000000754 repressing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 210000001044 sensory neuron Anatomy 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- ZNJHFNUEQDVFCJ-UHFFFAOYSA-M sodium;2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid;hydroxide Chemical compound [OH-].[Na+].OCCN1CCN(CCS(O)(=O)=O)CC1 ZNJHFNUEQDVFCJ-UHFFFAOYSA-M 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 210000003594 spinal ganglia Anatomy 0.000 description 1
- 210000000273 spinal nerve root Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000004895 subcellular structure Anatomy 0.000 description 1
- 238000000856 sucrose gradient centrifugation Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 230000030968 tissue homeostasis Effects 0.000 description 1
- 230000011199 transformed cell apoptotic process Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 230000002476 tumorcidal effect Effects 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F02—COMBUSTION ENGINES; HOT-GAS OR COMBUSTION-PRODUCT ENGINE PLANTS
- F02B—INTERNAL-COMBUSTION PISTON ENGINES; COMBUSTION ENGINES IN GENERAL
- F02B75/00—Other engines
- F02B75/02—Engines characterised by their cycles, e.g. six-stroke
- F02B2075/022—Engines characterised by their cycles, e.g. six-stroke having less than six strokes per cycle
- F02B2075/027—Engines characterised by their cycles, e.g. six-stroke having less than six strokes per cycle four
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/368,704 US6087160A (en) | 1993-06-24 | 1995-01-04 | Programmed cell death genes and proteins |
| PCT/US1996/000177 WO1996020721A1 (en) | 1995-01-04 | 1996-01-04 | Programmed cell death genes and proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO973107D0 NO973107D0 (no) | 1997-07-03 |
| NO973107L true NO973107L (no) | 1997-08-26 |
Family
ID=23452396
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO973107A NO973107L (no) | 1995-01-04 | 1997-07-03 | Programmerte celledödgener og proteiner |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US6087160A (es) |
| EP (1) | EP0808169A4 (es) |
| JP (1) | JPH11500304A (es) |
| AU (1) | AU4747296A (es) |
| CA (1) | CA2209526A1 (es) |
| FI (1) | FI972821A (es) |
| IL (1) | IL116671A0 (es) |
| MX (1) | MX9705039A (es) |
| NO (1) | NO973107L (es) |
| WO (1) | WO1996020721A1 (es) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993025685A1 (en) * | 1992-06-12 | 1993-12-23 | Massachusetts Institute Of Technology | Cloning and characterization of the cell death genes ced-3 and ced-4 |
| US6015665A (en) * | 1995-02-13 | 2000-01-18 | The Regents Of The University Of Michigan | Method and composition for regulating apoptosis |
| US6060238A (en) * | 1995-02-13 | 2000-05-09 | The Regents Of The University Of Michigan | Method and composition for regulating apoptosis |
| US7097972B1 (en) | 1995-02-13 | 2006-08-29 | Regents Of The University Of Michigan | Method and composition for regulating apoptosis |
| US7807783B1 (en) | 1995-04-03 | 2010-10-05 | The Regents Of The University Of Michigan | Methods and compositions for regulating FAS-associated apoptosis |
| US6747138B1 (en) | 1995-04-03 | 2004-06-08 | Regents Of The University Of Michigan | Methods and compositions for regulating Fas-associated apoptosis |
| US6214572B1 (en) * | 1996-08-09 | 2001-04-10 | The General Hospital Corporation | Programmed cell death and ICH-3 |
| US5897992A (en) | 1996-09-27 | 1999-04-27 | Cold Spring Harbor Laboratory | Cell-free assay using oncogene-induced apoptosis in drug-resistant cells |
| US6184210B1 (en) | 1997-10-10 | 2001-02-06 | Cytovia, Inc. | Dipeptide apoptosis inhibitors and the use thereof |
| US6342611B1 (en) | 1997-10-10 | 2002-01-29 | Cytovia, Inc. | Fluorogenic or fluorescent reporter molecules and their applications for whole-cell fluorescence screening assays for capsases and other enzymes and the use thereof |
| US6153591A (en) * | 1998-03-16 | 2000-11-28 | Cytovia, Inc. | Dipeptide caspase inhibitors and the use thereof |
| AU751167B2 (en) * | 1998-04-16 | 2002-08-08 | General Hospital Corporation, The | Programmed cell death and caspase-12 |
| EP1100520B1 (en) | 1998-07-21 | 2004-09-22 | Cytovia, Inc. | Novel fluorescence dyes and their applications for whole cell fluorescence screening assays for caspases, peptidases, proteases and other enzymes and the use thereof |
| ATE336480T1 (de) | 1999-03-16 | 2006-09-15 | Cytovia Inc | Substituierte 2-aminobenzamin caspase inhibitoren und ihre verwendung |
| AU4213500A (en) | 1999-04-09 | 2000-11-14 | Cytovia, Inc. | Caspase inhibitors and the use thereof |
| US6462041B1 (en) | 1999-05-21 | 2002-10-08 | Cytovia, Inc. | Gambogic acid, analogs and derivatives as activators of caspases and inducers of apoptosis |
| EP1212295B1 (en) | 1999-08-27 | 2008-10-01 | Cytovia, Inc. | Substituted alpha-hydroxy acid caspase inhibitors and the use thereof |
| US6566338B1 (en) | 1999-10-12 | 2003-05-20 | Cytovia, Inc. | Caspase inhibitors for the treatment and prevention of chemotherapy and radiation therapy induced cell death |
| JP2003513967A (ja) | 1999-11-05 | 2003-04-15 | サイトビア インコーポレイテッド | カスパーゼのアクチベーターおよびアポトーシスのインデューサーとしての置換４ｈクロメンおよびアナログ、ならびにその使用 |
| JP2003520854A (ja) | 2000-01-27 | 2003-07-08 | サイトビア インコーポレイテッド | カスパーゼのアクチベーターおよびアポトーシスのインデューサーとしての置換ニコチンアミドおよび類似物およびそれらの使用 |
| CA2406271A1 (en) | 2000-04-18 | 2001-10-25 | Cytovia, Inc. | Substituted 1,4-thiazepine and analogs and their use as activators of caspases |
| WO2002012496A1 (fr) * | 2000-08-03 | 2002-02-14 | Japan As Represented By The President Of The University Of Tokyo | Nouvelle proteine dependante de p53 et associee a l'apoptose et procede de balayage d'un agent de regulation de l'apoptose |
| AU2001278135A1 (en) | 2000-08-03 | 2002-02-18 | Cytovia, Inc. | Method of identifying immunosuppressive agents |
| AU2001289068A1 (en) * | 2000-09-20 | 2002-04-02 | Isis Pharmaceuticals, Inc. | Antisense modulation of caspase 2 expression |
| US6716851B2 (en) | 2000-12-12 | 2004-04-06 | Cytovia, Inc. | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof |
| ATE450531T1 (de) | 2001-05-16 | 2009-12-15 | Cytovia Inc | Substituierte 4h-chromene und analoga als aktivatoren von caspasen und induktoren von apoptose, und deren verwendung als antikrebsmittel |
| WO2002098420A1 (en) * | 2001-06-01 | 2002-12-12 | Cytovia, Inc. | 4-substituted-1-(arylmethylidene)thiosemicarbazide, 4-substituted-1-(arylcarbonyl)thiosemicarbazide and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| RU2003138074A (ru) | 2001-06-08 | 2005-02-20 | Цитови Инк. (US) | Замещенные 3-арил-5-арил-[1,2,4]-оксадиазолы и их аналоги в качестве активаторов каспаз и индукторов апоптоза, а также их применение |
| WO2003097806A2 (en) | 2002-05-16 | 2003-11-27 | Cytovia, Inc. | Substituted 4-aryl-4h-pyrrolo[2,3-h]chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| US7476741B2 (en) | 2002-05-16 | 2009-01-13 | Cytovia, Inc. | Substituted 4H-chromens, 2H-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| EP1581213A4 (en) | 2002-12-18 | 2008-11-19 | Cytovia Inc | 3,5-DISUBSTITUES-1,2,4-OXADIAZOLES AND ANALOGS AS ACTIVATORS OF CASPASES AND APOPTOSIS PROMOTERS, AND USE THEREOF |
| NZ544472A (en) | 2003-07-03 | 2009-04-30 | Myriad Genetics Inc | Compounds and therapeutical use thereof |
| CN1954882A (zh) * | 2005-10-14 | 2007-05-02 | 李海 | 长效人重组可溶性肿瘤坏死因子α受体在制备防治肝衰竭药物中的用途 |
| US10345292B2 (en) | 2014-09-09 | 2019-07-09 | Boehringer Ingelheim Animal Health Inc. | Mammalian cell lines expressing functional nematode acetylcholine receptors and use thereof for high-throughput screening assays |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7775991A (en) * | 1990-04-04 | 1991-10-30 | Immunex Corporation | Interleukin 1beta protease |
| EP0533350B1 (en) * | 1991-08-16 | 1999-05-26 | Merck & Co. Inc. | DNA encoding precursor interleukin 1B converting enzyme |
| ATE257517T1 (de) * | 1991-08-30 | 2004-01-15 | Vertex Pharma | Interleukin 1-beta protease und ihre inhibitoren |
| GB9124986D0 (en) * | 1991-11-25 | 1992-01-22 | Greenberg Arnold H | Natural killer cell granule protein |
| WO1993025685A1 (en) * | 1992-06-12 | 1993-12-23 | Massachusetts Institute Of Technology | Cloning and characterization of the cell death genes ced-3 and ced-4 |
| EP0672151A1 (en) * | 1992-06-12 | 1995-09-20 | Massachusetts Institute Of Technology | Inhibitors of ced-3 and related proteins |
| WO1995000160A1 (en) * | 1993-06-24 | 1995-01-05 | The General Hospital Corporation | Programmed cell death genes and proteins |
| WO1996000297A1 (en) * | 1994-06-23 | 1996-01-04 | Human Genome Sciences, Inc. | INTERLEUKIN-1 β CONVERTING ENZYME LIKE APOPTOSIS PROTEASE-1 AND 2 |
-
1995
- 1995-01-04 US US08/368,704 patent/US6087160A/en not_active Expired - Fee Related
- 1995-06-02 US US08/459,455 patent/US20030124105A1/en not_active Abandoned
-
1996
- 1996-01-04 IL IL11667196A patent/IL116671A0/xx unknown
- 1996-01-04 CA CA002209526A patent/CA2209526A1/en not_active Abandoned
- 1996-01-04 AU AU47472/96A patent/AU4747296A/en not_active Abandoned
- 1996-01-04 MX MX9705039A patent/MX9705039A/es not_active IP Right Cessation
- 1996-01-04 JP JP8521228A patent/JPH11500304A/ja active Pending
- 1996-01-04 WO PCT/US1996/000177 patent/WO1996020721A1/en not_active Application Discontinuation
- 1996-01-04 EP EP96903363A patent/EP0808169A4/en not_active Withdrawn
-
1997
- 1997-06-30 FI FI972821A patent/FI972821A/fi unknown
- 1997-07-03 NO NO973107A patent/NO973107L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| FI972821A (fi) | 1997-09-03 |
| AU4747296A (en) | 1996-07-24 |
| IL116671A0 (en) | 1996-05-14 |
| US20030124105A1 (en) | 2003-07-03 |
| MX9705039A (es) | 1997-10-31 |
| EP0808169A4 (en) | 2002-09-11 |
| US6087160A (en) | 2000-07-11 |
| NO973107D0 (no) | 1997-07-03 |
| WO1996020721A1 (en) | 1996-07-11 |
| EP0808169A1 (en) | 1997-11-26 |
| JPH11500304A (ja) | 1999-01-12 |
| FI972821A0 (fi) | 1997-06-30 |
| CA2209526A1 (en) | 1996-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO973107L (no) | Programmerte celledödgener og proteiner | |
| WO1996020721A9 (en) | Programmed cell death genes and proteins | |
| WO1995000160A1 (en) | Programmed cell death genes and proteins | |
| Miura et al. | Induction of apoptosis in fibroblasts by IL-1β-converting enzyme, a mammalian homolog of the C. elegans cell death gene ced-3 | |
| Shaham et al. | Developing Caenorhabditis elegans neurons may contain both cell-death protective and killer activities. | |
| Shaham et al. | Mutational analysis of the Caenorhabditis elegans cell-death gene ced-3 | |
| Moechars et al. | Expression in brain of amyloid precursor protein mutated in the alpha‐secretase site causes disturbed behavior, neuronal degeneration and premature death in transgenic mice. | |
| US8314067B1 (en) | Relatedness of human interleukin-1β convertase gene to a C. elegans cell death gene, inhibitory portions of these genes and uses therefor | |
| US7071302B1 (en) | Cloning sequencing and characterization of two cell death genes and uses therefor | |
| US5962301A (en) | Relatedness of human interleukin-1β convertase gene to a C. elegans cell death gene, inhibitory portions of these genes and uses therefor | |
| US6214572B1 (en) | Programmed cell death and ICH-3 | |
| WO1998006263A9 (en) | Programmed cell death and ich-3 | |
| AU696039C (en) | Programmed cell death genes and proteins | |
| AU2247200A (en) | Programmed cell death genes and proteins | |
| WO1999037770A1 (en) | Phagocytosis genes and uses thereof | |
| AU7071698A (en) | Methods and reagents for modulating apoptosis | |
| US6642368B1 (en) | Programmed cell death and caspase-12 | |
| US6939850B2 (en) | Altered human interleukin-1β convertase (ICE), NEDD-2, and C. elegans ced-3 polypeptides and uses therefor | |
| US6995252B2 (en) | PT32 sperm protein, sperm c-Yes, oocyte cytoplasmic c-Yes and uses thereof | |
| Shaham | Genetic and molecular studies of programmed cell death in the nematod Caenorhabditis elegans | |
| MXPA00007149A (es) | Genes de la fagocitosis y utilizaciones de los mismos | |
| JP2003525569A (ja) | 貪食作用遺伝子およびその使用 | |
| JP2001502171A (ja) | インターロイキン―１β変換酵素様のシステインプロテアーゼ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |